-
1
-
-
84855185039
-
Standards of medical care in diabetes-2012
-
Standards of medical care in diabetes-2012. Diabetes Care 2012; 35(Suppl 1): S11-S63.
-
(2012)
Diabetes Care
, vol.35
, Issue.SUPPL. 1
-
-
-
2
-
-
64349083605
-
Diabetes prevalence and therapeutic target achievement in the United States, 1999 to 2006
-
Cheung BMY, Ong KL, Cherny SS, Sham P-C, Tso AWK, Lam KSL. Diabetes prevalence and therapeutic target achievement in the United States, 1999 to 2006. Am J Med 2009; 122: 443-453.
-
(2009)
Am J Med
, vol.122
, pp. 443-453
-
-
Cheung, B.M.Y.1
Ong, K.L.2
Cherny, S.S.3
Sham, P.-C.4
Tso, A.W.K.5
Lam, K.S.L.6
-
3
-
-
83655184782
-
Achieving a clinically relevant composite outcome of an HbA1c of <7% without weight gain or hypoglycaemia in type 2 diabetes: a meta-analysis of the liraglutide clinical trial programme
-
Zinman B, Schmidt WE, Moses A, Lund N, Gough S. Achieving a clinically relevant composite outcome of an HbA1c of <7% without weight gain or hypoglycaemia in type 2 diabetes: a meta-analysis of the liraglutide clinical trial programme. Diabetes Obes Metab 2012; 14: 77-82.
-
(2012)
Diabetes Obes Metab
, vol.14
, pp. 77-82
-
-
Zinman, B.1
Schmidt, W.E.2
Moses, A.3
Lund, N.4
Gough, S.5
-
4
-
-
15444367142
-
Pharmacokinetics, pharmacodynamics, and safety of exenatide in patients with type 2 diabetes mellitus
-
Kolterman OG, Kim DD, Shen L et al. Pharmacokinetics, pharmacodynamics, and safety of exenatide in patients with type 2 diabetes mellitus. Am J Health Syst Pharm 2005; 62: 173-181.
-
(2005)
Am J Health Syst Pharm
, vol.62
, pp. 173-181
-
-
Kolterman, O.G.1
Kim, D.D.2
Shen, L.3
-
5
-
-
38549162147
-
Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years
-
Klonoff DC, Buse JB, Nielsen LL et al. Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years. Curr Med Res Opin 2008; 24: 275-286.
-
(2008)
Curr Med Res Opin
, vol.24
, pp. 275-286
-
-
Klonoff, D.C.1
Buse, J.B.2
Nielsen, L.L.3
-
6
-
-
4344713643
-
Effect of intravenous infusion of exenatide (synthetic exendin-4) on glucose-dependent insulin secretion and counterregulation during hypoglycaemia
-
Degn KB, Brock B, Juhl CB et al. Effect of intravenous infusion of exenatide (synthetic exendin-4) on glucose-dependent insulin secretion and counterregulation during hypoglycaemia. Diabetes 2004; 53: 2397-2403.
-
(2004)
Diabetes
, vol.53
, pp. 2397-2403
-
-
Degn, K.B.1
Brock, B.2
Juhl, C.B.3
-
7
-
-
53249142132
-
Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study
-
Drucker DJ, Buse JB, Taylor K et al. Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study. Lancet 2008; 372: 1240-1250.
-
(2008)
Lancet
, vol.372
, pp. 1240-1250
-
-
Drucker, D.J.1
Buse, J.B.2
Taylor, K.3
-
8
-
-
77955573674
-
Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial
-
Bergenstal RM, Wysham C, MacConell L et al. Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial. Lancet 2010; 376: 431-439.
-
(2010)
Lancet
, vol.376
, pp. 431-439
-
-
Bergenstal, R.M.1
Wysham, C.2
MacConell, L.3
-
9
-
-
77953859640
-
Once weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes (DURATION-3): an open-label randomised trial
-
Diamant M, Van Gaal L, Stranks S et al. Once weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes (DURATION-3): an open-label randomised trial. Lancet 2010; 375: 2234-2243.
-
(2010)
Lancet
, vol.375
, pp. 2234-2243
-
-
Diamant, M.1
Van Gaal, L.2
Stranks, S.3
-
10
-
-
33748442464
-
Interim analysis of the effects of exenatide treatment on A1C, weight and cardiovascular risk factors over 82weeks in 314 overweight patients with type 2 diabetes
-
Blonde L, Klein EJ, Han J et al. Interim analysis of the effects of exenatide treatment on A1C, weight and cardiovascular risk factors over 82weeks in 314 overweight patients with type 2 diabetes. Diabetes Obes Metab 2006; 8: 436-447.
-
(2006)
Diabetes Obes Metab
, vol.8
, pp. 436-447
-
-
Blonde, L.1
Klein, E.J.2
Han, J.3
-
11
-
-
84867344249
-
Safety of exenatide once weekly in patients with type 2 diabetes mellitus treated with a thiazolidinedione alone or in combination with metformin for 2 years
-
Norwood P, Liutkus JF, Haber H, Pintilei E, Boardman MK, Trautmann ME. Safety of exenatide once weekly in patients with type 2 diabetes mellitus treated with a thiazolidinedione alone or in combination with metformin for 2 years. Clin Ther 2012; 34: 2082-2090.
-
(2012)
Clin Ther
, vol.34
, pp. 2082-2090
-
-
Norwood, P.1
Liutkus, J.F.2
Haber, H.3
Pintilei, E.4
Boardman, M.K.5
Trautmann, M.E.6
-
12
-
-
0031578033
-
Recommendations guiding physicians in biomedical research involving human subjects
-
World Medical Association Declaration of Helsinki
-
World Medical Association Declaration of Helsinki. Recommendations guiding physicians in biomedical research involving human subjects. JAMA 1997; 277: 925-926.
-
(1997)
JAMA
, vol.277
, pp. 925-926
-
-
-
13
-
-
33846025092
-
Primary prevention of cardiovascular diseases in people with diabetes mellitus: a scientific statement from the American Heart Association and the American Diabetes Association
-
Buse JB, Ginsberg HN, Bakris GL et al. Primary prevention of cardiovascular diseases in people with diabetes mellitus: a scientific statement from the American Heart Association and the American Diabetes Association. Diabetes Care 2007; 30: 162-172.
-
(2007)
Diabetes Care
, vol.30
, pp. 162-172
-
-
Buse, J.B.1
Ginsberg, H.N.2
Bakris, G.L.3
-
14
-
-
78650733949
-
Cardiovascular comorbidities of type 2 diabetes mellitus: defining the potential of glucagonlike peptide-1-based therapies
-
Chilton R, Wyatt J, Nandish S, Oliveros R, Lujan M. Cardiovascular comorbidities of type 2 diabetes mellitus: defining the potential of glucagonlike peptide-1-based therapies. Am J Med 2011; 124: S35-S53.
-
(2011)
Am J Med
, vol.124
-
-
Chilton, R.1
Wyatt, J.2
Nandish, S.3
Oliveros, R.4
Lujan, M.5
-
15
-
-
84860638209
-
The cardiovascular effects of GLP-1 receptor agonists
-
Okerson T, Chilton RJ. The cardiovascular effects of GLP-1 receptor agonists. Cardiovasc Ther 2012; 30: e146-e155.
-
(2012)
Cardiovasc Ther
, vol.30
-
-
Okerson, T.1
Chilton, R.J.2
-
16
-
-
33748471110
-
Long-term effects of exenatide therapy over 82weeks on glycaemic control and weight in over-weight metformin-treated patients with type 2 diabetes mellitus
-
Ratner RE, Maggs D, Nielsen LL et al. Long-term effects of exenatide therapy over 82weeks on glycaemic control and weight in over-weight metformin-treated patients with type 2 diabetes mellitus. Diabetes Obes Metab 2006; 8: 419-428.
-
(2006)
Diabetes Obes Metab
, vol.8
, pp. 419-428
-
-
Ratner, R.E.1
Maggs, D.2
Nielsen, L.L.3
-
17
-
-
67649854490
-
Improved glycaemic control and reduction of cardiometabolic risk factors in subjects with type 2 diabetes and metabolic syndrome treated with exenatide in a clinical practice setting
-
Bhushan R, Elkind-Hirsch KE, Bhushan M, Butler WJ, Duncan K, Marrioneaux O. Improved glycaemic control and reduction of cardiometabolic risk factors in subjects with type 2 diabetes and metabolic syndrome treated with exenatide in a clinical practice setting. Diabetes Technol Ther 2009; 11: 353-359.
-
(2009)
Diabetes Technol Ther
, vol.11
, pp. 353-359
-
-
Bhushan, R.1
Elkind-Hirsch, K.E.2
Bhushan, M.3
Butler, W.J.4
Duncan, K.5
Marrioneaux, O.6
-
18
-
-
81855221189
-
Exenatide BID Observational Study (ExOS): results for primary and secondary endpoints of a prospective research study to evaluate the clinical effectiveness of exenatide BID use in patients with type 2 diabetes in a real-world setting
-
Bergenstal RM, Garrison LP, Miller LA et al. Exenatide BID Observational Study (ExOS): results for primary and secondary endpoints of a prospective research study to evaluate the clinical effectiveness of exenatide BID use in patients with type 2 diabetes in a real-world setting. Curr Med Res Opin 2011; 27: 2335-2342.
-
(2011)
Curr Med Res Opin
, vol.27
, pp. 2335-2342
-
-
Bergenstal, R.M.1
Garrison, L.P.2
Miller, L.A.3
-
19
-
-
70450203583
-
Six-month outcomes on A1C and cardiovascular risk factors in patients with type 2 diabetes treated with exenatide in an ambulatory care setting
-
Brixner DI, McAdam-Marx C, Ye X et al. Six-month outcomes on A1C and cardiovascular risk factors in patients with type 2 diabetes treated with exenatide in an ambulatory care setting. Diabetes Obes Metab 2009; 11: 1122-1130.
-
(2009)
Diabetes Obes Metab
, vol.11
, pp. 1122-1130
-
-
Brixner, D.I.1
McAdam-Marx, C.2
Ye, X.3
-
20
-
-
67549112400
-
Insights from the liraglutide clinical development program-the liraglutide effect and action in diabetes (LEAD) studies
-
McGill JB. Insights from the liraglutide clinical development program-the liraglutide effect and action in diabetes (LEAD) studies. Postgrad Med 2009; 121: 16-25.
-
(2009)
Postgrad Med
, vol.121
, pp. 16-25
-
-
McGill, J.B.1
-
21
-
-
79952694840
-
Cardiovascular safety of exenatide BID: an integrated analysis from controlled clinical trials in participants with type 2 diabetes
-
Ratner R, Han J, Nicewarner D, Yushmanova I, Hoogwerf BJ, Shen L. Cardiovascular safety of exenatide BID: an integrated analysis from controlled clinical trials in participants with type 2 diabetes. Cardiovasc Diabetol 2011; 10: 22.
-
(2011)
Cardiovasc Diabetol
, vol.10
, pp. 22
-
-
Ratner, R.1
Han, J.2
Nicewarner, D.3
Yushmanova, I.4
Hoogwerf, B.J.5
Shen, L.6
-
22
-
-
79951702236
-
Risk of cardiovascular disease events in patients with type 2 diabetes prescribed the glucagon-like peptide 1 (GLP-1) receptor agonist exenatide twice daily or other glucose-lowering therapies: a retrospective analysis of the LifeLink database
-
Best JH, Hoogwerf BJ, Herman WH et al. Risk of cardiovascular disease events in patients with type 2 diabetes prescribed the glucagon-like peptide 1 (GLP-1) receptor agonist exenatide twice daily or other glucose-lowering therapies: a retrospective analysis of the LifeLink database. Diabetes Care 2011; 34: 90-95.
-
(2011)
Diabetes Care
, vol.34
, pp. 90-95
-
-
Best, J.H.1
Hoogwerf, B.J.2
Herman, W.H.3
-
23
-
-
80052039077
-
Cardiovascular safety of liraglutide assessed in a patient-level pooled analysis of phase 2: 3 liraglutide clinical development studies
-
Marso SP, Lindsey JB, Stolker JM et al. Cardiovascular safety of liraglutide assessed in a patient-level pooled analysis of phase 2: 3 liraglutide clinical development studies. Diab Vasc Dis Res 2011; 8: 237-240.
-
(2011)
Diab Vasc Dis Res
, vol.8
, pp. 237-240
-
-
Marso, S.P.1
Lindsey, J.B.2
Stolker, J.M.3
-
24
-
-
79959259385
-
Glucagon-like peptide-1 receptor agonists and cardiovascular events: a meta-analysis of randomized clinical trials
-
Monami M, Cremasco F, Lamanna C et al. Glucagon-like peptide-1 receptor agonists and cardiovascular events: a meta-analysis of randomized clinical trials. Exp Diabetes Res 2011; 2011: 215764.
-
(2011)
Exp Diabetes Res
, vol.2011
, pp. 215764
-
-
Monami, M.1
Cremasco, F.2
Lamanna, C.3
-
25
-
-
84871697848
-
Exenatide once weekly for the treatment of type 2 diabetes mellitus: clinical results in subgroups of patients using different concomitant medications
-
Pencek R, Brunell SC, Li Y, Hoogwerf BJ, Malone J. Exenatide once weekly for the treatment of type 2 diabetes mellitus: clinical results in subgroups of patients using different concomitant medications. Postgrad Med 2012; 124: 33-40.
-
(2012)
Postgrad Med
, vol.124
, pp. 33-40
-
-
Pencek, R.1
Brunell, S.C.2
Li, Y.3
Hoogwerf, B.J.4
Malone, J.5
-
26
-
-
34247647418
-
Nonalcoholic fatty liver disease is a novel predictor of cardiovascular disease
-
Hamaguchi M, Kojima T, Takeda N et al. Nonalcoholic fatty liver disease is a novel predictor of cardiovascular disease. World J Gastroenterol 2007; 13: 1579-1584.
-
(2007)
World J Gastroenterol
, vol.13
, pp. 1579-1584
-
-
Hamaguchi, M.1
Kojima, T.2
Takeda, N.3
-
27
-
-
34247605492
-
Prevalence of nonalcoholic fatty liver disease and its association with cardiovascular disease among type 2 diabetic patients
-
Targher G, Bertolini L, Padovani R et al. Prevalence of nonalcoholic fatty liver disease and its association with cardiovascular disease among type 2 diabetic patients. Diabetes Care 2007; 30: 1212-1218.
-
(2007)
Diabetes Care
, vol.30
, pp. 1212-1218
-
-
Targher, G.1
Bertolini, L.2
Padovani, R.3
-
28
-
-
0036829752
-
American Gastroenterological Association medical position statement: nonalcoholic fatty liver disease
-
American Gastroenterological Association medical position statement: nonalcoholic fatty liver disease. Gastroenterology 2002; 123: 1702-1704.
-
(2002)
Gastroenterology
, vol.123
, pp. 1702-1704
-
-
|